Glenn Sblendorio

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ.

NuLens Ltd. is engaged in to researching, developing and marketing the novel accommodative Intraocular Lens ('IOL') technology. The Company is focused on exploiting the novel technologies in its patents and developing a real accommodative IOL ('RA-IOL') with the unparalleled capacity of providing over 10 Diopters of accommodative power to the cataract market and a legitimate candidate for the treatment of presbyopia, a vision disorder involving the inability of the eye to focus on near activities such as reading a newspaper or finding a number in a phone book. The company was founded by Joshua Ben-Nun in September 2002 and is headquartered in Herzliya Pituach, Israel.

Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA.